Free Trial

Quince Therapeutics (QNCX) Competitors

Quince Therapeutics logo
$1.63 +0.02 (+1.24%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.69 +0.06 (+3.68%)
As of 08/22/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QNCX vs. ZYBT, ADCT, BNTC, FDMT, INBX, CADL, LRMR, RCKT, AMRN, and ALDX

Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Rocket Pharmaceuticals (RCKT), Amarin (AMRN), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry.

Quince Therapeutics vs. Its Competitors

Zhengye Biotechnology (NASDAQ:ZYBT) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Quince Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 8 mentions for Quince Therapeutics and 6 mentions for Zhengye Biotechnology. Quince Therapeutics' average media sentiment score of 0.68 beat Zhengye Biotechnology's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zhengye Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quince Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zhengye Biotechnology's return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Quince Therapeutics N/A -187.49%-42.47%

Zhengye Biotechnology has higher revenue and earnings than Quince Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$25.53M12.90$1.55MN/AN/A
Quince TherapeuticsN/AN/A-$56.83M-$1.09-1.50

Quince Therapeutics has a consensus target price of $8.14, indicating a potential upside of 399.56%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Quince Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.30

30.8% of Quince Therapeutics shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNCX vs. The Competition

MetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$86.48M$3.11B$5.76B$9.58B
Dividend YieldN/A2.23%4.41%4.10%
P/E Ratio-1.5020.8831.1026.04
Price / SalesN/A348.74435.03103.40
Price / CashN/A43.1937.7358.48
Price / Book7.418.129.536.61
Net Income-$56.83M-$54.72M$3.26B$265.56M
7 Day Performance-3.55%2.63%2.10%1.97%
1 Month Performance-12.37%2.78%2.82%-0.36%
1 Year Performance146.97%11.01%30.56%19.03%

Quince Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QNCX
Quince Therapeutics
3.1116 of 5 stars
$1.63
+1.2%
$8.14
+399.6%
+154.3%$86.48MN/A-1.5060
ZYBT
Zhengye Biotechnology
N/A$7.84
+4.4%
N/AN/A$354.22M$25.53M0.00278News Coverage
Gap Down
ADCT
ADC Therapeutics
1.9924 of 5 stars
$3.24
+3.5%
$7.75
+139.2%
+12.2%$352.12M$70.84M-2.06310High Trading Volume
BNTC
Benitec Biopharma
1.3659 of 5 stars
$12.71
-2.3%
$26.00
+104.6%
+44.3%$341.52M$80K-8.4220News Coverage
FDMT
4D Molecular Therapeutics
2.0835 of 5 stars
$7.27
+0.1%
$30.40
+318.2%
-51.0%$339.06M$40K-2.06120
INBX
Inhibrx Biosciences
1.6841 of 5 stars
$23.87
+2.3%
N/A+92.5%$337.95M$200K-2.26166Analyst Forecast
Short Interest ↓
CADL
Candel Therapeutics
2.5579 of 5 stars
$5.96
-2.1%
$22.00
+269.1%
+12.1%$334.31M$120K-8.6460
LRMR
Larimar Therapeutics
2.2011 of 5 stars
$3.90
-2.7%
$18.43
+372.5%
-49.3%$331.94MN/A-2.5030
RCKT
Rocket Pharmaceuticals
4.8792 of 5 stars
$3.03
-0.7%
$16.33
+439.1%
-80.3%$329.11MN/A-1.21240Analyst Forecast
Analyst Revision
AMRN
Amarin
0.2855 of 5 stars
$16.17
+3.3%
$12.00
-25.8%
+29.9%$324.07M$228.61M-4.41360
ALDX
Aldeyra Therapeutics
2.0566 of 5 stars
$5.44
+0.9%
$9.50
+74.6%
+11.1%$322.84MN/A-6.4010

Related Companies and Tools


This page (NASDAQ:QNCX) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners